Tocilizumab (Actemra, Roche) is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R) approved for the treatment of seriously ill COVID-19 patients with elevated IL-6 by the National Health Commission of China. The gene discussed is IL6; the disease is COVID-19.